Actualités et Activités de Deciphera Pharmaceuticals
Présence
Siège : Etats—Unis
ONO Pharmaceutical fait partie des...
ONO Pharmaceutical est une société cotée sous le symbole boursier 4528 (JP).
ONO Pharmaceutical a une présence directe dans 2 pays.
Acquisition, funding and merger involving ONO Pharmaceutical.
Dirigeants
Voir l'organigramme avec ses 27 principaux dirigeants
Biographies les plus recherchées chez Deciphera Pharmaceuticals
- Ryota Udagawa, Chief Executive Officer and President
- Toichi Takino, Director
- Masayuki Tanigawa, Director
Changements de dirigeants chez Deciphera Pharmaceuticals
- Cynthia Fairbairn, Director, Clinical Operations, a quitté l'entreprise (publié le 3 avril 2026).
- Margarida Duarte, Executive Vice President and Global Chief Commercial Officer, a quitté l'entreprise (publié le 3 avril 2026).
- Lisa Amaya Price, Senior Vice President and Chief Human Resources Officer, a quitté l'entreprise (publié le 13 janvier 2026).
Changements de dirigeants chez ONO Pharmaceutical
- Toshihiro Tsujinaka qui était Executive Director, Corporate Strategy & Planning, devient Representative Director, Senior Executive Officer, Chief Officer of CMC & Production (publié le 3 mars 2026).
- Harumi Nakano qui était Senior Director, Corporate Strategy & Planning, Business Management, devient Corporate Officer, Senior Director, Finance & Accounting Department (publié le 3 mars 2026).
- Masaki Itoh qui était Corporate Officer, Division Director, Corporate Strategy & Planning, Business Management Division, Business Management Department and President, Ono Digital health Investment, devient Corporate Executive Officer, Chief Officer of Finance & Accounting (publié le 3 mars 2026).
Cliquez ici pour voir d'autres changements chez ONO Pharmaceutical
Créer une alerte
pour suivre les mouvements de dirigeants chez Deciphera Pharmaceuticals.
Pharmacie
ONO Pharmaceutical a 1 913 concurrents dont Sanofi (France), Eli Lilly (Etats—Unis) et Moderna (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Contraline vient d'annoncer une levée de fonds de 93 millions de dollars. (publié le 3 juin 2026).
- Hims & Hers a acquis Eucalyptus (publié le 2 juin 2026).
- Apotex a déposé son dossier d'introduction en bourse. Son symbole boursier sera TSX. (publié le 2 juin 2026).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Deciphera Pharmaceuticals
- Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022 | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022 | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants | Deciphera Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Deciphera Pharmaceuticals
- Deciphera Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Deciphera Pharmaceuticals sur LinkedIn, X (Twitter) & YouTube en 1-click
